ClinicalTrials.gg
Active, not recruitingNCT03194815SINAPPS2Updated May 22, 2026

IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

A Phase 2 interventional study of Intravenous immunoglobulin and Placebo in Psychosis and Autoimmune Encephalitis, sponsored by University of Cambridge. Active, not recruiting at 10 sites in United Kingdom. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by University of Cambridge · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Psychotic Disorders with a site in United Kingdom — 19 open to participants now, 22 under way, 4 of them phase 3. Psychotic Disorders · United Kingdom.

Planned enrollment
26th of 60
70 · median 59
Started
2017
with 9 others
Phase 2
2 of 75
none open now
Primary completion
2027-04
later than 9 of 21 live
Registered
25th of 75
by date
Lead sponsor
3 of 75
University of Cambridge

Among the 75 studies in Psychotic Disorders with a site in United Kingdom, this one is the 26th largest by planned enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2017, is one of 2 in phase 2, reaches primary completion later than 9 of the 21 other live ones, and was the 25th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

19 of the 75 studies in Psychotic Disorders with a site in United Kingdom are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Psychotic Disorders with a site in United Kingdom, or all of them as a file.
02

Study summary

A randomised phase II double-blinded placebo-controlled trial designed to explore the utility of immunotherapy for patients with acute psychosis associated with anti-neuronal membranes (NMDA-receptor or Voltage Gated Potassium Channel).

Primary objective: To test the efficacy of immunotherapy (IVIG and rituximab) for patients with acute psychosis associated with anti-neuronal membranes.

Secondary objective: To test safety of immunotherapy (IVIG and rituximab) for patients with acute psychosis associated with anti-neuronal membranes.

Read the detailed description

Investigators propose a randomised double-blinded placebo-controlled trial to test the hypothesis that immunotherapy is an effective treatment of antibody-associated psychosis, either first episode of psychosis or relapse following previous remission. Immunotherapy for the trial consists of one cycle of intravenous immunoglobulin (IVIG: 2g/kg over days 1-4) followed by two infusions of 1g rituximab (at day 28-35, and then 14 days after the first infusion). The rationale for this regime is that it combines a rapid-action treatment (IVIG) to induce remission with a longer-action therapy (rituximab) to maintain remission. It is based on a protocol where elimination of circulating antibodies is the treatment goal, namely "desensitisation" of potential transplant patients who have multiple anti-HLA antibodies capable of inducing hyperacute rejection and also being tested in various trials on clinicaltrials.gov (NCT00642655, NCT01178216, and NCT01502267). Blinding is required to minimise placebo responses in a trial based on symptomatology.

03

Conditions studied

  • Psychosis
  • Autoimmune Encephalitis

Keywords

  • Psychosis
  • Immunotherapy
  • Autoantibodies
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute psychosis >2 weeks. This may either be first episode or relapse after remission (remission defined as having mild or absent symptoms of psychosis for at least 6 months)
  • Serum or CSF neuronal membrane autoantibodies at pathological levels (including NMDAR, LGI1 and other)
  • Psychosis symptoms as defined by PANSS ≥4 on at least one of the following items: P1, P2, P3, N1, N4, N6, G5 and G9.

Exclusion criteria

Exclusion Criteria:

  • Current episode of psychosis greater than 24 months duration
  • Co-existing severe neurological disease
  • Evidence of current acute encephalopathy
  • Hepatitis or infection, pregnancy
  • to any trial drug
  • Concurrent enrolment in another CTIMP
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Intravenous immunoglobulin and Rituximab

    One cycle of intravenous immunoglobulin (IVIG) 2g/kg over 2-5 days (days 1-5) followed by (b) two infusions of 1g rituximab (the first infusion starting between days 28-35, and the second infusion 14 days later), each with 100mg methylprednisolone.

    Drug: Intravenous immunoglobulin · Drug: Rituximab

  • Placebo comparator
    Placebo

    One cycle of 0.9% saline solution over 2-5 days (days 1-5) followed by (b) two infusions of placebo solution alongside placebo pill - in equal volumes to steroid pre-medication and rituximab.

    Drug: Placebo

Interventions

  • DrugImmunoglobulins, IntravenousStudies of Immunoglobulins, IntravenousImmunoglobulins, Intravenous pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This is a blood product containing antibodies from thousands of healthy donors.

    Also known as: IVIG, Intratect

  • DrugPlacebo

    This is the control, or sham, treatment

    Also known as: Saline solution

  • Rituximab is a type of biological therapy. It removes B-cells and helps to reduce the inflammation

    Also known as: MabThera

06

What researchers measure

Primary outcomes

  1. Time to start of symptomatic recovery (symptomatic remission sustained for at least 6 months)

    remission defined as Positive and Negative Syndrome Scale (PANSS) score 3 or less on PANSS items P1, P2, P3, N1, N4, N6, G5 and G9 sustained for 6 months

    Time frame: up to 18 months

Secondary outcomes

  1. Time to first treatment response (whether sustained or not)

    Treatment response defined as score of 3 or less on each of the following PANSS items: P1, P2, P3, N1, N4, N6, G5, and G9.

    Time frame: up to 18 months

  2. Relapse rate

    Relapse rate is defined as a score 4 or more on PANSS items P1, P2, P3, N1, N4, N6, G5, and G9.

    Time frame: 18 months

  3. Number of adverse effects

    total number of patient reported adverse effects

    Time frame: 18 months

  4. Proportion of patients reaching 20% reduction in PANSS total score

    20% reduction in the PANSS total score (all PANNS items included)

    Time frame: 12 months

  5. Proportion of patients reaching 30% reduction in PANSS total score

    30% reduction in the PANSS total score (all PANNS items included)

    Time frame: 12 months

  6. Proportion of patients reaching 40% reduction in PANSS total score

    40% reduction in the PANSS total score (all PANNS items included)

    Time frame: 12 months

  7. Changes in the Clinical Global Impression Scale in Schizophrenia (CGI-Schizophrenia)

    Change in CGI-Schizophrenia scores from baseline to month 12

    Time frame: 12 months

  8. Changes in the Young Mania Rating Scale (YMRS)

    Change in YMRS total score from baseline to month 12

    Time frame: 12 months

  9. Changes in the Antipsychotic Non-Neurological Side-Effects Rating Scale (ANNSERS)

    Change in ANNSERS total score from baseline to month 12

    Time frame: 12 months

  10. Changes in the Brief Assessment of Cognition in Schizophrenia (BACS)

    Change in BACS scores from baseline to month 12

    Time frame: 12 months

  11. Changes in the Global Assessment of Functioning scale (GAF)

    Change in the GAF score from baseline to month 12

    Time frame: 12 months

07

Study locations

10 sites
08

References and documents

Publications

  • Lennox B, Yeeles K, Jones PB, Zandi M, Joyce E, Yu LM, Tomei G, Pollard R, Vincent SA, Shimazaki M, Cairns I, Dowling F, Kabir T, Barnes TRE, Lingford Hughes A, Hosseini AA, Harrower T, Buckley C, Coles A. Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2). Trials. 2019 Jun 7;20(1):331. doi: 10.1186/s13063-019-3336-1. PubMed 31174586 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2017 (actual). Primary completion is estimated for Apr 2027, 113 months after the start.

Of 28 non-industry phase 2 interventional studies under Psychotic Disorders, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 53. This study's planned 113 months is above that.

Counting every sponsor, half of 39 studies reached it within 39 months; a quarter within 22 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2017
First posted
Jun 21, 2017
StartActual
Nov 1, 2017
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03194815
Responsible party
Alasdair Coles (Revd. Prof. Alasdair Coles, Chief Investigator, University of Cambridge) — Principal investigator
First posted
Jun 21, 2017
Start date
Nov 1, 2017
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Alasdair Coles, PhD FRCP
principal investigator · University of Cambridge, UK

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Immunoglobulins, Intravenous · Rituximab

Start the discussion